These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11892911)

  • 1. Oritavancin. Eli Lilly & Co.
    Barrett JF
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1039-44. PubMed ID: 11892911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
    Henson KE; Levine MT; Wong EA; Levine DP
    Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of oritavancin and related glycopeptide antibiotics.
    Allen NE; Nicas TI
    FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
    Bouza E; Burillo A
    Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
    Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Preobrazhenskaya MN
    J Med Chem; 2003 Mar; 46(7):1204-9. PubMed ID: 12646030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
    Van Bambeke F
    Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMR-3562. Aventis Pharma.
    Ma Z; Florjancic AS
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1702-5. PubMed ID: 11892931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oritavancin--an investigational glycopeptide antibiotic.
    Ward KE; Mersfelder TL; LaPlante KL
    Expert Opin Investig Drugs; 2006 Apr; 15(4):417-29. PubMed ID: 16548791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semisynthetic glycopeptides: chemistry, structure-activity relationships and prospects.
    Ciabatti R; Malabarba A
    Farmaco; 1997 May; 52(5):313-21. PubMed ID: 9274002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
    Crandon J; Nicolau DP
    Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Coyle EA; Rybak MJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):706-9. PubMed ID: 11181347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
    Van Bambeke F
    Ann Med; 2014 Nov; 46(7):512-29. PubMed ID: 25058176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.
    Arhin FF; McKay GA; Beaulieu S; Sarmiento I; Parr TR; Moeck G
    Int J Antimicrob Agents; 2009 Dec; 34(6):550-4. PubMed ID: 19818587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.
    Arhin FF; Belley A; McKay GA; Moeck G
    Curr Protoc Microbiol; 2010 Feb; Chapter 17():Unit17.1. PubMed ID: 20131224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.